| 翻訳と辞書 |
| Jeremy Levin ： ウィキペディア英語版 |
Jeremy Levin
Jeremy Levin (born 1954), is a South African-born businessman, medical doctor and research scientist. Dr. Levin has been recognized for his accomplishments in the biopharmaceutical industry, being named one of the most influential people in the industry.〔http://www.fiercebiotech.com/special-reports/25-most-influential-people-biopharma-today/jeremy-levin-25-most-influential-people-b〕
==Career==
Dr. Levin is the Chairman and CEO of Ovid Therapeutics Inc., a company dedicated to providing innovative medicines to children and adults with neurological disorders.〔http://www.ovidrx.com/press-release/ovid-therapeutics-appoints-dr-jeremy-levin-as-chief-executive-officer〕〔http://www.cnbc.com/id/102591288〕 Ovid’s initial product development programs are focused on orphan and rare diseases of the brain, including Angelman syndrome and Fragile X syndrome.
Prior to joining Ovid, Dr. Levin served as President and CEO of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), one of the world’s largest pharmaceutical companies.〔http://www.ynetnews.com/articles/0,7340,L-4170124,00.html〕〔http://articles.economictimes.indiatimes.com/2012-01-03/news/30584630_1_teva-pharmaceutical-industries-shlomo-yanai-cephalon〕Previously, he was a member of the Executive Committee of Bristol-Myers Squibb (NYSE:BMY), where he had global responsibilities for strategy, alliances and transactions.〔http://news.bms.com/press-release/jeremy-levin-joins-bristol-myers-squibb-senior-vice-president-external-science-technol〕 In this role, he devised and led BMY’s “String of Pearls” business development strategy. This strategy helped drive the transformation of BMY, particularly following the acquisition by Dr. Levin of Medarex Inc. in July 2009, which positioned BMY as a leader in immunooncology.〔http://seekingalpha.com/article/838671-bristol-myers-squibb-the-asset-problem-and-the-string-of-pearls〕〔http://www.bloomberg.com/news/articles/2012-01-02/teva-says-jeremy-levin-named-to-succeed-shlomo-yanai-as-ceo〕〔http://news.bms.com/press-release/partnering-news/bristol-myers-squibb-acquire-medarex〕Prior to this, Dr. Levin was Head of Global Business Development and Strategic Alliances at Novartis (NYSE: NVS), and previously served as Chairman and CEO of Cadus Pharmaceuticals, Inc.〔https://www.genomeweb.com/rnai/novartis-alnylam-deal-fulfills-long-term-plan-partner-rnai-drug-development〕〔http://www.secinfo.com/dr4ur.82w6.htm〕
Dr. Levin currently serves on the Boards of Biocon LTD and ZappRx.〔http://www.biocon.com/docs/DrLevin_Biocon_BOD.pdf〕〔http://medcitynews.com/2015/04/zapprx-raises-5-6m-series-pharma-companies-take-responsibility-specialty-drug-needs/〕〔http://www.twst.com/interview/10785〕Dr. Levin is a frequent speaker at biopharmaceutical conferences where his focus is driving deeper and more direct relationships between companies and patients, ensuring innovation in the biopharmaceutical industry, expanding the role of mergers and acquisitions, globalizing the biopharmaceutical industry, and propelling interface of the digital health and biopharmaceutical industries and leadership.〔https://www.youtube.com/watch?v=e4cDBjiFV_Y〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Jeremy Levin」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|